Guilford Pharmaceuticals Inc. [GLFD]
Opened The NASDAQ Stock Market
|
| |
Pictured:
Craig R. Smith, M.D., President and Chief Executive Officer of Guilford Pharmaceuticals Inc.
(NASDAQ: GLFD), presides over the Market Open.
|
Craig R. Smith, M.D.,
President and
Chief Executive Officer of
Guilford Pharmaceuticals Inc.
opened
The NASDAQ Stock Market
Thursday, August 28, 2003
at NASDAQ's MarketSite
in New York City.
Click here for more information on
Guilford Pharmaceuticals Inc.
|
| |
Additional Photographs & Reprint Permissions |
Archived MarketSite Events |
Summary Quote
The NASDAQ Stock Market proudly welcomes Dr. Smith and Guilford
Pharmaceuticals Inc. [GLFD] to the Market Open in celebration of the
company's 10-year business anniversary. Over the past ten years,
Guilford has been dedicated to the development and commercialization
of healthcare products to address important diseases in neurology.
About Guilford Pharmaceuticals Inc. [GLFD]
Guilford Pharmaceuticals Inc. is a fully integrated pharmaceutical
company engaged in the research, development and commercialization of
products that target the hospital and neurology markets. Presently,
Guilford markets one commercial product, GLIADEL(R) Wafer, for the
treatment of brain cancer, and has a product pipeline, which includes
a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating
Parkinson's disease and post-prostatectomy erectile dysfunction.
The Company now has two compounds in Phase II clinical testing --
AQUAVAN(TM), a novel prodrug of the world's best selling anesthetic
agent, propofol, and GPI 1485, the most advanced product in its class
to treat Parkinson's disease. AQUAVAN represents one of Guilford's
most closely watched programs, offering a number of potential
advantages over currently approved products. Interim results of the
first part of Phase II testing in patients undergoing conscious
sedation during colonoscopy are expected later this year. GPI 1485
is a novel approach to neuroprotection and was recently selected for
inclusion in a comprehensive clinical investigation of new therapies
for Parkinson's disease being conducted by the National Institute of
Neurological Disorders and Stroke of the NIH.
|
